Abstracts Archive - Page 221 of 2607 - ACR Meeting Abstracts

Abstract Number: 2689 • ACR Convergence 2024
Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis
Lynn Fussner¹, Ivan Bilic², Carol McAlear³, David Cuthbertson⁴, Jie Cheng⁵, Elise Chen⁵, Markus Weiller², Ulrich Specks⁶ and Peter Merkel³, and for the Vasculitis Clinical Research Consortium, ¹The Ohio State University, Columbus, OH, ²Takeda Pharmaceuticals, Vienna, Austria, ³University of Pennsylvania, Philadelphia, PA, ⁴University of South Florida, Tampa, FL, ⁵Takeda Pharmaceuticals, Cambridge, MA, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
Abstract Number: 2685 • ACR Convergence 2024
Association Between Gastrointestinal Bacterial Species and Radiological Features of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD): A Multicenter Study from the SSc Microbiome Consortium Project
Arissa Young¹, Kristofer Andreasson², Swapna Joshi³, Jen Labus³, Andrea Low Hsiu Ling⁴, vanessa smith⁵, Zsuzsanna McMahan⁶, Antonia Valenzuela Vergara⁷, Susanna Proudman⁸, Grace Kim³, Gracijela Bozovic², Jonathan Goldin³, Ezinne Aja³, Jonathan Jacobs³ and Elizabeth Volkmann⁹, ¹UCLA, Los Angeles, CA, ²Lund University, Lund, Sweden, ³UCLA, Los Angeles, ⁴3Singapore General Hospital, Duke-NUS, Singapore, Singapore, ⁵Ghent University Hospital, Gent, Belgium, ⁶UTHealth Houston Division of Rheumatology, Houston, TX, ⁷Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁸Royal Adelaide Hospital, Adelaide, Australia, ⁹University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Variations in gastrointestinal (GI) microbial communities may influence the development of lung diseases. Patients with SSc-ILD have a unique intestinal microbial signature. To further…
Abstract Number: PP10 • ACR Convergence 2024
Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally
Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY
Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…
Abstract Number: PP05 • ACR Convergence 2024
Reunion with Forgotten Relationships and Memories
Noriko Okochi¹, Eiji Oishi², Kaoru Mitsuyama³, Emi Sorimachi³, Shiho Bando⁴, Yuka Hirama⁵, Nobuyuki Yajima⁶ and Masaaki Mori⁷, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan, ³Institute of Neuropsychiatry, Tokyo, Tokyo, Japan, ⁴Ota-ku Children and Families Support Center, Ota-ku, Tokyo, Japan, ⁵Asada Ladies Clinic, Shinagawa, Japan, Tokyo, Japan, ⁶Showa-Universtiy of Medicine, Tokyo, Japan, ⁷Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Paediatric rheumatic diseases are complex experiences for children. For children whose language skills are still undeveloped, it is difficult for them to put their…
Abstract Number: 2668 • ACR Convergence 2024
Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
Silvia Cavalli¹, Fabricio Espinosa-Ortega², Ryan A. Adams³, Lauren Guy³, Charlotta Preger⁴, Càtia Fernandes-Cerqueira⁵, Roberto Caporali⁶, Ingrid Lundberg⁷ and Antonella Notarnicola⁸, ¹University of Milan, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet;5Structural Genomics Consortium, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁵4Dcell, Montrueil, Ile-de-France, France, ⁶Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…
Abstract Number: 2640 • ACR Convergence 2024
Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
Alexander Wu¹, Arianna Zhang², Yujia Guo¹, Jialing Liu¹, Donghan Yang¹, Lourdes Perez Chada³, Alexis Ogdie⁴, Jose Scher⁵ and Joseph Merola⁶, ¹University of Texas Southwestern Medical Center, Dallas, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Wayland, MA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Psoriatic arthritis is a chronic systemic inflammatory disorder with significant impacts on health and life quality. Achieving good disease control in psoriatic arthritis (PsA)…
Abstract Number: 2587 • ACR Convergence 2024
A Proprietary AI Rule Engine Assisted by an OpenAI-based ML Model Can Speed up and Better Inform the Prior Authorization Process for Rheumatology Investigations and Medications
Tanishka Agrawal¹, Sumanth Raman², J. Arun³ and HUMEIRA BADSHA⁴, ¹Dubai International Academy, Dubai, Dubai, United Arab Emirates, ²Algorithm Health, Dubai, Dubai, United Arab Emirates, ³Algorithm Health, Dubai, United Arab Emirates, ⁴HBMC, Dubai, United Arab Emirates
Background/Purpose: Patients with chronic autoimmune conditions often need expensive treatments which require prior authorizations by insurance companies. However, significant delays in these processes leave patients…
Abstract Number: 2686 • ACR Convergence 2024
Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
David Fox¹, Laura Cooney², Lia Stelzig³, Robert Lafyatis⁴, Johann Gudjonsson⁵, Lam Tsoi⁶, Maureen Mayes⁷, Ankoor Shah⁸, Suzanne Kafaja⁹, William Barry³, Ellen Goldmuntz¹⁰, Dawn Smilek¹¹ and Dinesh Khanna⁶, ¹University of Michigan, Dexter, MI, ²University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ³Rho, Durham, NC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, MI, ⁷UTHealth Houston Division of Rheumatology, Houston, TX, ⁸Duke University, Durham, NC, ⁹Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ¹⁰Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, ¹¹Immune Tolerance Network, UCSF, San Francisco, CA
Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…
Abstract Number: 2481 • ACR Convergence 2024
General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Rula A. Hajj-Ali¹, Duvuru Geetha², Raashid Luqmani³, Christian Pagnoux⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Cleveland Clinic, Cleveland, OH, ²Johns Hopkins University, Baltimore, MD, ³University of Oxford, Abingdon, United Kingdom, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: The most common types of ANCA-associated vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), can affect a range of organs, including the kidneys,…
Abstract Number: 2643 • ACR Convergence 2024
Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis
Kristina Clark¹, Corrado Campochiaro², Emma Derrett-Smith³, Voon Ong⁴, Christopher Buckley⁵ and Christopher Denton⁶, ¹University of Oxford, Oxford, United Kingdom, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³University College London Division of Medicine, Birmingham, United Kingdom, ⁴University College London, London, England, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁶University College London, Northwood, United Kingdom
Background/Purpose: Myofibroblasts are key cells in the pathogenesis of systemic sclerosis (SSc). TGFβ is a key growth factor driving myofibroblast formation in SSc. The main…
Abstract Number: 2598 • ACR Convergence 2024
p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines
Zhihua Ma, Luis Carvajal, Andrew Chen, Rosa Villagomez, Yare calderon, Tamara Hopkins, Hua Gao, Benjamin Trotter, Charles Lin and Peter Rahl, Kronos Bio, Cambridge, MA
Background/Purpose: Across inflammatory and autoimmune diseases, pathologic signaling converges in the nucleus to elevate transcription of numerous inflammatory effectors such as cytokines, chemokines and antibodies.…
Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
April Jorge¹, Aakash Patel¹, Baijun Zhou², Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
Abstract Number: 2617 • ACR Convergence 2024
Higher Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures, Analysis of Data from 2020 – 2022
Emma Kersey¹, Jing Li², Julia Adler-Milstein³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, ⁴UCSF, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: The American College of Rheumatology’s Rheumatology Informatics System for Effectiveness (RISE) web-based clinician dashboard enables quality performance monitoring and reporting in the Merit-Based Incentive…
Abstract Number: 2651 • ACR Convergence 2024
Vasculitis Associated with VEXAS Syndrome
Megan Sullivan¹, Kambiz Kalantari², Carolyn Mead-Harvey³, Yael Kusne⁴, Mrinal Patnaik², Abhishek Mangaonkar², Ronald Go², Daniel Montes², Kaaren Reichard², Horatiu Olteanu², Melanie Bois², Alexander Hines², Julio Sartori-Valinotti⁵, Kenneth Warrington² and Matthew Koster², ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Scottsdale, AZ, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic, Rohester, MN
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently defined clinical entity that causes hematologic and autoinflammatory symptoms. Since its initial description…
Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].